NCT06600789 is a Phase 1, PHASE2 clinical trial of CT7439 Capsules (0.5 mg, 1mg, 3mg) in Solid Malignancies, sponsored by Carrick Therapeutics Limited.

Who is sponsoring NCT06600789?

NCT06600789 is sponsored by Carrick Therapeutics Limited.

What drugs are being tested in NCT06600789?

Interventions in NCT06600789: CT7439 Capsules (0.5 mg, 1mg, 3mg).

What condition does NCT06600789 study?

NCT06600789 studies Solid Malignancies.

Is NCT06600789 still recruiting?

NCT06600789 is currently recruiting now. Last updated 3 November 2025.

Last reviewed 2025-11-03 · How we verify

NCT06600789

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies

Recruiting now Phase 1, PHASE2 Last updated 3 November 2025

What this trial tests

Phase 1, PHASE2 trial testing CT7439 Capsules (0.5 mg, 1mg, 3mg) in Solid Malignancies in 50 participants. Currently enrolling.

Timeline

16 August 2024

Primary endpoint
22 April 2026

22 May 2026

Quick facts

Lead sponsor	Carrick Therapeutics Limited
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	16 August 2024
Primary completion	22 April 2026
Estimated completion	22 May 2026
Sites	6 locations across United Kingdom, United States

Drugs / interventions tested

CT7439 Capsules (0.5 mg, 1mg, 3mg) — full drug profile →

Conditions studied

Solid Malignancies — all drugs for Solid Malignancies →

Sponsor

Carrick Therapeutics Limited — full company profile →

Who can join

18 and older, any sex, with Solid Malignancies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This modular, multi-part, multi-arm, Phase 1/2, FIH study allows the evaluation of the safety and tolerability of CT7439, dosed as a monotherapy and in combination with anticancer treatment in participants with solid malignancies.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

CDK12/13 inactivation triggers STING-mediated antitumor immunity in preclinical models.
Bao Y, Chang Y, Tien JC, Cruz G, et al · · 2025 · cited 4× · PMID 40955658 · DOI 10.1172/jci193745
Targeting CDK12/13 Drives Mitotic Arrest to Overcome Resistance to KRASG12C Inhibitors.
Stern YE, Ghosh P, Peroza J, Solanki HS, et al · · 2026 · cited 2× · PMID 41165466 · DOI 10.1158/0008-5472.can-25-0450
Differential activity of specific inhibitors of transcription regulating cyclin-dependent kinases in thyroid cancer cells.
Rajan N, Khanal T, Adik A, Valenciaga A, et al · · 2025 · cited 2× · PMID 40298170 · DOI 10.1530/erc-24-0124
Targeting CDK12 disrupts estrogen-receptor chromatin recruitment and ER-MED1 transcription in advanced ER+ breast cancer.
Ottaviani D, Ola M, Allotta A, Maati Chaibi Y, et al · · 2026 · cited 1× · PMID 41092317 · DOI 10.1093/jnci/djaf295
New insights into the dule roles CDK12 in human cancers: Mechanisms and interventions for cancer therapy.
Dai W, Xie D, Huang H, Li J, et al · · 2025 · cited 1× · PMID 40747342 · DOI 10.1016/j.jpha.2024.101173
Absence of synergistic effects by CDK12/13 inhibition in combination with cisplatin or olaparib in ovarian cancer cells.
Santer FR, Hovdar L, Handle F, Tsibulak I, et al · · 2026 · PMID 41922714 · DOI 10.1038/s41598-026-46634-3
Breast Cancer Brain Metastases: Current Understanding and Future Directions.
Alabdulrahman M, Daly GR, Naidoo S, Stuart L, et al · · 2026 · PMID 41642399 · DOI 10.1007/s11912-026-01753-y
CDK12 and CDK13 in oncology: from RNA regulation to therapeutic targeting.
Dudkiewicz-Garbicz J, Włodarski PK. · · 2026 · PMID 41491919 · DOI 10.1007/s13402-025-01131-z

Verify or expand the search:

Other recruiting trials for Solid Malignancies

Currently open trials in the same condition.

NCT06933069 — Safety and Tolerability of CMAB017 In Patients With Advanced Solid Tumors · Phase 1 · recruiting
NCT06684028 — PET Image Exploration of Novel Tracer [68Ga]-FAPI-JNU Imaging Studies in Patients with Malignant Tumors · NA · recruiting
NCT02537418 — Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemothe · Phase 1 · active not recruiting

Other Carrick Therapeutics Limited trials

Trials by the same sponsor.

NCT05963984 — A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Partici · Phase 2 · completed
NCT05963997 — A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Can · Phase 1, PHASE2 · completed
NCT03363893 — Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06600789 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Carrick Therapeutics Limited
Last refreshed: 3 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06600789.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing